1.
Tanasescu R, Frakich N, Chou I-J, et al. Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells. Neurology and therapy. 2023. doi:10.1007/s40120-023-00539-9.
1.
Bargiela D, Bianchi MT, Westover B, et al. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology. 2017;88(7):677-684. doi:10.1212/WNL.0000000000003612.